



HAL
open science

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort.

Marie-Elise Truchetet, Elodie Drumez, Thomas Barnetche, Claire Martin, Mathilde Devaux, Tiphaine Goulenok, Alexandre Maria, Jean Schmidt, Nassim Ait-Abdallah, Isabelle Melki, et al.

► **To cite this version:**

Marie-Elise Truchetet, Elodie Drumez, Thomas Barnetche, Claire Martin, Mathilde Devaux, et al.. Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort.. RMD Open : Rheumatic & Musculoskeletal Diseases, 2022, RMD Open : Rheumatic & Musculoskeletal Diseases, 8, 10.1136/rmdopen-2022-002476 . hal-04403670

HAL Id: hal-04403670

<https://hal.univ-lille.fr/hal-04403670>

Submitted on 18 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.





L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

ORIGINAL RESEARCH

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort

Marie-Elise Truchetet ¹, Elodie Drumez,² Thomas Barnetche,¹ Claire Martin,² Mathilde Devaux,³ Tiphaine Goulenok,⁴ Alexandre Maria,⁵ Jean Schmidt,^{6,7} Nassim Ait Abdallah,^{8,9} Isabelle Melki ^{10,11} Eric Hachulla ¹², Christophe Richez ¹

To cite: Truchetet M-E, Drumez E, Barnetche T, *et al.* Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort. *RMD Open* 2022;**8**:e002476. doi:10.1136/rmdopen-2022-002476

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2022-002476>).

Received 18 May 2022
Accepted 5 August 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Pr Marie-Elise Truchetet;
marie-elise.truchetet@chu-bordeaux.fr

ABSTRACT

Background Patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) receiving mycophenolic acid (MPA) may have a less favourable outcome from COVID-19 infection. Our aim was to investigate whether MPA treatment is associated with severe infection and/or death.

Methods iRMD patients with and without MPA treatment with highly suspected/confirmed COVID-19 were included in this observational multicentre study. The primary outcome was death rate from COVID-19 with secondary objectives to determine the severity of infection and length of hospital stay. Outcome comparisons were made using regression models with and without adjustment on prespecified confounding factors. ORs, sub-HR (sHR) and 95% CIs were calculated using patients not treated with MPA as a reference group.

Results Of the 1977 patients, 1928 were not treated with MPA (393 were MPA eligible), and 49 patients were treated with MPA. MPA-treated patients had more severe disease, longer hospital stays and higher death rate from COVID-19 than non-MPA patients (OR 8.02 (95% CI 3.35 to 19.20), $p < 0.001$; sHR 0.57 (95% CI 0.33 to 0.98), $p = 0.040$; OR 11.58 (95% CI 4.10 to 32.69), $p < 0.001$). In adjusted analyses, however, no outcome was independently associated with MPA treatment. Death rate, severity and length of hospital stay of MPA-treated patients were not significantly different from those of not treated but MPA-eligible patients.

Conclusion MPA therapy is not associated with a more severe COVID-19 infection. However, due to increased vulnerability of developing a severe form of COVID-19, careful consideration should be taken with iRMD patients likely to be treated with MPA.

Trial registration number NCT04353609.

INTRODUCTION

Throughout the pandemic, physicians who treat patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) have

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ In the COVID-19 Global Rheumatology Alliance registry analysis, immunosuppressive agents (mycophenolic acid (MPA), but not synthetic/biological targeted disease-modifying antirheumatic drugs), have been pinpointed as providing an increased risk of death from COVID-19 when compared with standard of care methotrexate.
- ⇒ However, whether patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) receiving MPA treatment have a higher risk of COVID-19 related death remains controversial due to inconsistencies among clinical studies.

WHAT DOES THIS STUDY ADD

- ⇒ In age and sex adjusted analyses, iRMD patients treated with MPA had similar disease severity, length of hospital stay and death rate following COVID-19 infection to iRMD patients not treated with MPA.
- ⇒ Our study demonstrates that iRMD patients have increased risk of a poor outcome from COVID-19, but this risk is likely due to confounding factors, not MPA therapy.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ MPA use should be continued in iRMD patients without fear of an increased risk of severe COVID-19.
- ⇒ Patients receiving MPA are also the most vulnerable to severe COVID-19, and vaccination against COVID-19 should be a priority, with a close follow-up monitoring of the vaccine response.

been concerned their patients would develop more severe forms of the COVID-19 disease due to the disruption of their immune systems as a result of their illness or treatment.¹ The first preliminary published data on this aspect were reassuring in refuting this concern.² In a recent systematic review to

inform the European Alliance of Associations for Rheumatology recommendations, patients with rheumatic musculoskeletal diseases (RMDs) do not face worse prognosis of COVID-19 than individuals without RMDs.³ However, these data are in disagreement with those obtained in the Global Rheumatology Alliance (GRA) database analysis, which showed that RMD patients with moderate to high disease activity had a higher risk of COVID-19 related death.⁴ Subsequent recommendations stated that there was no evidence that patients with RMD were at higher risk of SARS-CoV-2 infection than individuals without RMDs or have an inferior prognosis with a COVID-19 diagnosis.⁵ In an analysis of the French RMD COVID-19 cohort, which includes iRMD patients with highly suspected or confirmed diagnosis of COVID-19, older age, male gender, obesity, hypertension and interstitial lung disease (ILD) were found to be associated with severe COVID-19, similar to those observed for the general population.⁶ In this cohort, the use of methotrexate or TNF α and IL-6 inhibitors was not related to severe infection, but use of corticosteroids at high doses was linked with more severe disease.⁶ A potential risk of more severe COVID-19 in patients treated by rituximab (RTX) or by mycophenolic acid (MPA; the pharmacologically active ingredient in mycophenolate sodium or mycophenolate mofetil, both of which are used to treat patients in France) has been suspected. Recent analysis has confirmed the increased risk with RTX,⁷ and in the COVID-19 GRA registry, immunosuppressive agents (comprising MPA but not synthetic/biological targeted disease-modifying antirheumatic drugs) have been pinpointed as increasing the risk of a death from COVID-19 when compared with methotrexate.⁴

Currently, treatment with MPA is used under very specific conditions in iRMD, which is characterised by a higher risk of poor prognosis, including connective tissue disorders, with pulmonary or renal involvement.^{8,9} Whether iRMD patients treated with MPA have a higher risk of developing severe COVID-19 is still unclear. We hypothesised that iRMD patients are more vulnerable to more severe disease following SARS-Cov-2 infection regardless of their MPA treatment status. Thus, the aim of this study was to investigate whether treatment with MPA by itself is associated with increased disease severity and/or death rate in the French RMD COVID-19 cohort.

PATIENTS AND METHODS

Study design and patients

This is an observational, multicentre study of the French RMD cohort, which has been previously described.⁶ Briefly, the cohort enrolled participants ≥ 18 years old patients with confirmed RMD with highly suspected/confirmed diagnosis of COVID-19.¹⁰

Data collection

All cases of highly suspected/confirmed iRMD-COVID-19 patients were reported retrospectively. The individual

data regarding iRMD diagnosis/specific treatments were captured from physicians via a national data entry portal. Data collection from the patient's medical record was previously described.⁶ Data cut-off was 20 August 2021, and the final database was monitored to collect missing data, validate the evolution of COVID-19, remove duplicate or erroneous reports and check data consistency.

Outcomes

The primary endpoint was the death rate from COVID-19. Secondary outcomes were severity of the infection and the length of hospital stay. Severity of COVID-19 was assessed at least 21 days after the first clinical sign of COVID-19 and classified according to the care needed for each patient: mild=ambulatory; moderate=hospitalised out of intensive care unit (ICU); and severe=ICU or deceased. These outcomes were compared between MPA-treated patients and patients not treated with MPA, as well between MPA-treated patients and patients not treated with MPA but who were eligible for MPA treatment (MPA eligible subgroup). A patient was defined as eligible for MPA treatment when affected with a disease that may potentially be treated with MPA according to standard of care recommendations or previous evidence-based medical treatment (ie, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, vasculitis associated with cytoplasmic anti-neutrophil antibodies, IgG4-related disease, mixed connective tissue disease, primary Sjögren syndrome, other vasculitis or eye inflammation).

Statistical analysis

Categorical variables were expressed as numbers (percentage) and continuous variables as mean \pm SD. Length of hospital stay was estimated using a competing risk survival analysis approach (Kalbfleisch and Prentice method)¹⁰ to account for hospital mortality, by estimating the cumulative incidence of discharge alive, treating death as the competing event. We compared outcomes between groups (MPA-treated group vs group with no MPA treatment and MPA-treated group vs MPA eligible subgroup) using multinomial logistic regression model for severity outcome measure (a three-level categorical variable), using binary logistic regression model for binary outcomes (death) and using Fine and Gray regression model for length of hospital stay, with discharge alive as the event of interest and hospital death as the competing event. Analyses were adjusted for age and sex and then for all prespecified confounding factors (ie, age, sex, arterial hypertension, body mass index (BMI), interstitial lung disease (ILD), cardiovascular diseases, corticoid treatment (three-level categorical variable defined as no corticoid treatment, <10 mg treatment and ≥ 10 mg treatment) and chronic renal failure). To consider all prespecified confounding factors, we made comparisons by using the propensity score overlap weighting (PSOW) method, which allows for consideration of extreme propensity scores.¹¹ We estimated the propensity score using a multivariable logistic

regression model, with study groups as dependent variables including all prespecified confounding factors. OR and sub-HR (sHR) and the corresponding 95% CIs were calculated as effect size using patients not treated with MPA as reference groups. To avoid case deletion in analyses, missing data for outcomes and prespecified confounding factors were imputed by simple imputation using the regression-switching approach. The imputation procedure was performed under the missing-at-random assumption, with predictive mean-matching method for continuous variables and logistic regression (binary, ordinal or multinomial) models for categorical variables. To test the robustness of our models, we performed bootstrap resampling analysis (200 resamples from the original database) as sensitivity analysis. The method consist to calculate in 200 replicates the propensity score to provide the PSOW adjusted p values for each outcomes comparison in each replicates; the median and 95% CI (ie, the 2.5th and 97.5th percentile) of PSOW adjusted p-values of the 200 replicates were reported. All statistical tests were performed at the two-tailed α level of 0.05 using SAS software, release V.9.4 (SAS Institute).

RESULTS

A total of 1977 records were collected, all with available final evaluation of COVID-19 outcome (table 1). As a cohort, patients were predominately female (66.6%), with a mean age of 55 ± 17 years (52.2% (n=1033) were ≥ 55 years old) and 68.1% of the patients had at least one comorbidity (n=1343), with hypertension (n=474, 24.0%), obesity (BMI ≥ 30 kg/m², n=438, 24.7%), respiratory disease (n=269, 13.6%) and cardiac disease (n=222, 11.2%) among the most common.

Among the cohort, 49 patients were treated with MPA, mainly for systemic lupus erythematosus (n=22, 44.9%) and systemic sclerosis (SSc) (n=18, 36.7%). Two control groups were considered for comparison with MPA-treated patients: the first included all patients not treated with MPA (n=1928) and the second consisted of a subgroup of patients not treated with MPA but eligible for MPA treatment (n=393). The mean age of the patients was 45 ± 15 years in the MPA treated group, 56 ± 17 years in the patients not treated with MPA and 55 ± 18 years in the MPA-eligible subgroup. ILD was present in 34.7% of the MPA-treated patients (n=17/49), 4.0% of the patients not treated with MPA (n=77/1928) and 8.7% of the MPA eligible subgroup (n=34/393) as shown in table 1. Moreover, chronic renal failure was present in 18.4% of the MPA-treated patients (n=9/49), but only 4.4% of the patients not treated with MPA (n=85/1928) and 10.2% of the MPA-eligible subgroup (n=40/393). Corticosteroids were prescribed to more than 70% of the MPA-treated patients (n=35/49) and to less than 30% of the patients not treated (n=530/1928). In each of the three patient groups, the proportion of patients receiving more than 10 mg/day of corticosteroids was approximately 40%.

In the MPA-treated group, 18.4% of patients (n=9/49) were classified as having a severe COVID-19 infection, with 11.1% (n=219/1928) in the not treated with MPA group and 14.3% (n=56/393) in the not treated MPA eligible subgroup having been documented with the same COVID-19 severity. In the age-sex adjusted analyses, MPA-treated patients had an increased risk of presenting a moderate and severe form of COVID-19 compared with patients not treated with MPA: OR for moderate versus mild: 3.57 (95% CI 1.76 to 7.21), $p < 0.001$, and OR for severe versus mild: 8.02 (95% CI 3.35 to 19.20), $p < 0.001$ (table 2). After adjusting for potential confounding factors using the PSOW (online supplemental figure 1), no differences in severity were confirmed in the MPA-treated group compared with the group not treated with MPA: OR for moderate versus mild: 1.18 (95% CI 0.40 to 3.45), OR for severe versus mild: 1.18 (95% CI 0.34 to 4.05) (table 2). Furthermore, MPA-treated patients presented no differences for severity compared with subgroup (OR for moderate vs mild: 0.83 (95% CI 0.27 to 2.50); OR for severe vs mild: 1.20 (95% CI 0.32 to 4.40); table 3). In bootstrapping analyses, the median of PSOW adjusted p values for comparison of severity was 0.70 (2.5th to 97.5th percentiles, 0.13 to 1.00) in overall population and 0.63 (2.5th to 97.5th percentiles, 0.11 to 0.98) in the eligible population.

The median length of hospital stay was 9.0 (IQR 4.0 to 19.0) in the MPA-treated group, 10.0 (IQR 5.0 to 26.0) in patients not treated with MPA and 10.0 (IQR 6.0 to 32.0) in the treatment-eligible subgroup. In the age-adjusted and sex-adjusted analyses, a lower length of hospital stay was found in treated group compared with group of patients not treated with MPA (sHR 0.57 (95% CI 0.33 to 0.98), $p = 0.040$; table 2), but no differences were found in treated group compared with the eligible subgroup (sHR 0.74 (95% CI 0.42 to 1.31); table 3). After adjusting for potential confounding factors by PSOW, no differences were confirmed in the MPA-treated group compared with the group not treated with MPA (sHR 0.87 (95% CI 0.41 to 1.84); table 2) or the eligible subgroup (sHR 0.93 (95% CI 0.42 to 2.05); table 3). In bootstrapping analyses, the median of PSOW adjusted p values for comparison of severity was 0.63 (2.5th to 97.5th percentiles, 0.14 to 0.98) in overall population and 0.64 (2.5th to 97.5th percentiles, 0.15 to 0.98) in the eligible population.

Six (12.2%) patients died in the MPA treatment group, 119 (6.2%) in the group not treated with MPA and 37 (9.4%) in the eligible subgroup. In the age-adjusted and sex-adjusted analyses, MPA-treated patients presented higher risk of death compared with patients not treated with MPA (OR 11.58 (95% CI 4.10 to 32.69), $p = 0.001$; table 2) and eligible subgroup (OR 4.94 (95% CI 1.59 to 15.34), $p = 0.006$; table 3). After adjusting for potential confounding factors by PSOW, no difference in outcomes were detected between the MPA-treated group compared with the group not treated (OR 1.38 (95% CI 0.30 to 6.20); table 2) or the eligible subgroup (OR 1.31 (95% CI 0.28 to 5.95); table 3). In bootstrapping analyses, the median

Table 1 Patient characteristics

	Overall (n=1977)	MPA (n=49)	No MPA (n=1928)	MPA eligible* (n=393)
Age (years)				
18–54	944 (47.7)	36 (73.5)	908 (47.1)	189 (48.1)
55–64	412 (20.8)	7 (14.3)	405 (21.0)	66 (16.8)
65–74	352 (17.8)	5 (10.2)	347 (18.0)	75 (19.1)
≥75	269 (13.6)	1 (2.0)	268 (13.9)	63 (16.0)
Mean±SD	55.3±16.6	44.9±14.6	55.6±16.6	54.9±18.1
Female gender	1317 (66.6)	36 (73.5)	1281 (66.4)	301 (76.6)
Comorbidities††				
Respiratory disease (all)	269 (13.6)	19 (38.8)	250 (13.0)	64 (16.3)
Interstitial lung disease	94 (4.8)	17 (34.7)	77 (4.0)	34 (8.7)
COPD	79 (4.0)	2 (4.1)	77 (4.0)	18 (4.6)
Asthma	115 (5.8)	1 (2.0)	114 (5.9)	18 (4.6)
Cardiac disease (all)	222 (11.2)	9 (18.4)	213 (11.1)	61 (15.5)
Coronary heart disease	183 (9.3)	5 (10.2)	178 (9.2)	49 (12.5)
Stroke	56 (2.8)	5 (10.2)	51 (2.6)	17 (4.3)
Diabetes	195 (9.9)	1 (2.0)	194 (10.1)	39 (9.9)
BMI (kg/m ²)				
<30	1342 (75.4)	32 (71.1)	1310 (75.5)	293 (80.1)
30–39.9	389 (21.9)	13 (28.9)	376 (21.7)	65 (17.8)
≥40	49 (2.8)	0 (0.0)	49 (2.8)	8 (2.2)
Mean±SD	26.4±5.5	26.3±5.3	26.4±5.5	25.8±5.5
Hypertension	474 (24.0)	9 (18.4)	465 (24.2)	102 (26.0)
Cancer	71 (3.6)	0 (0.0)	71 (3.7)	25 (6.4)
Smoking	187 (9.5)	4 (8.2)	183 (9.5)	37 (9.4)
Chronic renal failure	94 (4.8)	9 (18.4)	85 (4.4)	40 (10.2)
No. of patients with at least one comorbidity	1343 (68.1)	44 (89.8)	1 299 (67.5)	272 (69.2)
Disease history				
Systemic lupus	134 (6.8)	22 (44.9)	112 (5.8)	112 (28.5)
Systemic sclerosis	76 (3.8)	18 (36.7)	58 (3.0)	58 (14.8)
Others	835 (42.2)	2 (4.1)	833 (43.2)	33 (8.4)
Other vasculitis	143 (7.2)	2 (4.1)	141 (7.3)	49 (12.5)
Inflammatory myopathy	30 (1.5)	2 (4.1)	28 (1.5)	28 (7.1)
Mixed connective tissue disease	12 (0.6)	2 (4.1)	10 (0.5)	10 (2.5)
Eye inflammation	3 (0.2)	1 (2.0)	2 (0.1)	2 (0.5)
Rheumatoid arthritis	643 (32.5)	0 (0.0)	643 (33.4)	0 (0.0)
Primary Sjögren syndrome	56 (2.8)	0 (0.0)	56 (2.9)	56 (14.2)
Vasculitis associate	41 (2.1)	0 (0.0)	41 (2.1)	41 (10.4)
IgG4-related disease	4 (0.2)	0 (0.0)	4 (0.2)	4 (1.0)
Rheumatic disease or AI ² D treatments				
Corticosteroid	565 (28.6)	35 (71.4)	530 (27.5)	181 (46.1)
Systemic corticosteroid doses ≥10 mg	211 (37.7)	13 (37.1)	198 (37.7)	80 (44.4)
NSAIDs	167 (8.4)	0 (0.0)	167 (8.7)	12 (3.1)
Colchicine	77 (3.9)	0 (0.0)	77 (4.0)	20 (5.1)
Hydroxychloroquine	181 (9.2)	21 (42.9)	160 (8.3)	129 (32.8)

Continued

Table 1 Continued

	Overall (n=1977)	MPA (n=49)	No MPA (n=1928)	MPA eligible* (n=393)
Methotrexate	687 (34.7)	0 (0.0)	687 (35.6)	64 (16.3)
Leflunomide	73 (3.7)	0 (0.0)	73 (3.8)	3 (0.8)
Salazopyrine	24 (1.2)	0 (0.0)	24 (1.2)	2 (0.5)
Azathioprine	26 (1.3)	0 (0.0)	26 (1.3)	21 (5.3)
IVIGs	9 (0.5)	2 (4.1)	7 (0.4)	7 (1.8)
Biologicals				
Anti-TNF	563 (28.5)	0 (0.0)	563 (29.2)	12 (3.1)
Anti-IL6	75 (3.8)	1 (2.0)	74 (3.8)	4 (1.0)
Anti-IL17a	60 (3.0)	0 (0.0)	60 (3.1)	1 (0.3)
Anti-IL1	15 (0.8)	0 (0.0)	15 (0.8)	1 (0.3)
Anti-CD20	111 (5.6)	1 (2.0)	110 (5.7)	52 (13.2)
Abatacept	45 (2.3)	0 (0.0)	45 (2.3)	1 (0.3)
JAK inhibitor	76 (3.8)	0 (0.0)	76 (3.9)	1 (0.3)
Other biologicals	37 (1.9)	2 (4.1)	35 (1.8)	10 (2.5)

Values are presented as n (percentage) unless otherwise indicated.

*The eligible subgroup included patients who did not receive MPA despite having diseases for which MPA is a recognised therapeutic option.

†3 missing values for comorbidities (in no MPA treatment group) except for BMI where 197 values are missing (treated group: n=4; no MPA treatment group: n=193; eligible subgroup: n=27).

AI²D, autoimmune and autoinflammatory diseases; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IL, interleukin; IVIGs, intravenous immunoglobulins; JAK, janus kinase; MPA, mycophenolic acid; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.

of PSOW adjusted p values for comparison of severity was 0.60 (2.5th to 97.5th percentiles, 0.13 to 0.98) in overall population and 0.62 (2.5th to 97.5th percentiles, 0.16 to 0.99) in the eligible population.

DISCUSSION

In the present study, we demonstrate that there was no difference among our three study groups in terms of

severity, length of hospital stay or death rate from COVID-19. Based on our findings, we claim that the overall excess risk of poor outcome of COVID-19 in patients treated with MPA in an iRMD population after age and sex adjustment is likely due to confounding factors.

When the first alerts about the risk of severe COVID-19 in patients treated with immunosuppressive drugs were published, it was crucial to determine whether this

Table 2 Outcomes of patients treated with MPA and patients that were not treated with MPA

	MPA (n=49)	No MPA (n=1928)	Age-sex adjusted		PSOW adjusted *	
			Effect size (95% CI)	P value	Effect size (95% CI)	P value
Severity				<0.001		0.94
Mild	26 (53.1)	1306 (67.7)	1.00 (ref.)	–	1.00 (ref.)	–
Moderate	14 (28.6)	408 (21.2)	3.57 (1.76 to 7.21)†	<0.001	1.18 (0.40 to 3.45) †	0.77
Severe	9 (18.4)	214 (11.1)	8.02 (3.35 to 19.20)†	<0.001	1.18 (0.34 to 4.05) †	0.79
Length of hospital stay, median (IQR)	9.0 (4.0 to 19.0)	10.0 (5.0 to 26.0)	0.57 (0.33 to 0.98)‡	0.040	0.87 (0.41 to 1.84)‡	0.72
Death	6 (12.2)	119 (6.2)	11.58 (4.10 to 32.69)†	<0.001	1.38 (0.30 to 6.20)†	0.67

Values are presented as n (percentage) unless otherwise indicated. Values, effect size and p values were calculated after handle missing data by simple imputation.

*Effect size and p values calculated using propensity score overlap weighting analyses, using no MPA treatment group as reference.

†OR calculated using multinomial or binary logistic regression models.

‡Sub-HR (sHR) calculated among 645 hospitalised patients using Fine and Gray model with discharge alive as the event of interest and hospital death as the competing event. sHR >1 indicates an increase in length of hospital stay, and an sHR <1 indicates a decrease in length of hospital stay compared with the reference group.

MPA, mycophenolic acid; PSOW, propensity score overlap weighting.

Table 3 Outcomes of MPA-treated patients and MPA-eligible patients

	MPA (n=49)	MPA eligible* (n=393)	Age-sex adjusted		PSOW adjusted†	
			Effect size (95% CI)	P value	Effect size (95% CI)	P value
Severity				0.038		0.88
Mild	26 (53.1)	211 (53.7)	1.00 (ref.)	–	1.00 (ref.)	–
Moderate	14 (28.6)	126 (32.1)	1.39 (0.67 to 2.88)‡	0.37	0.83 (0.27 to 2.50)‡	0.74
Severe	9 (18.4)	56 (14.3)	3.43 (1.33 to 8.83)‡	0.011	1.20 (0.32 to 4.40)‡	0.78
Length of hospital stay, median (IQR)	9.0 (4.0 to 19.0)	10.0 (6.0 to 32.0)	0.74 (0.42 to 1.31)§	0.30	0.93 (0.42 to 2.05)§	0.86
Death	6 (12.2)	37 (9.4)	4.94 (1.59 to 15.34)‡	0.006	1.31 (0.28 to 5.95)‡	0.73

Values are presented as n (percentage) unless otherwise indicated. Values, effect size and p values were calculated after handle missing data by simple imputation.

*The MPA eligible group included patients in the no MPA treatment group who did not receive treatment despite having diseases for which treatment is a recognised therapeutic option.

†Effect size and p values calculated using propensity score overlap weighting analyses, using MPA eligible subgroup as reference.

‡OR calculated using multinomial or binary logistic regression models.

§Sub-HR (sHR) calculated among 205 hospitalised patients using Fine and Gray model with discharge alive as the event of interest and hospital death as the competing event. sHR >1 indicates an increase in length of hospital stay, and an sHR <1 indicates a decrease in length of hospital stay compared with the reference group.

MPA, mycophenolic acid; PSOW, propensity score overlap weighting;

increased risk was related to the molecule itself or to other confounding factors. An analysis of the French iRMD cohort showed that treatment with RTX could be considered an independent risk factor for the development of severe COVID-19,⁷ which has since been confirmed by others.¹² Apart from RTX, other commonly prescribed immunosuppressive drugs, and in particular MPA, have been suspected to be linked with poor COVID-19 outcomes, even after gender and age adjusted analyses.⁴ Raw data of the French RMD cohort suggested that the course of the COVID-19 infection was less favourable with MPA than that described with other targeted treatments, such as TNF α blockers, with the possibility of severe forms.⁶ Analysis of the French cohort data after the addition of nearly 1000 patients confirmed this finding after adjustment for sex and age. An analysis by the GRA in a population of lupus patients showed a similar result after adjustment for sex and age.¹² While the question of specifically protecting at-risk populations through isolation or vaccination arises, it is very important to conclude the direct impact of MPA, which is especially used in fragile patient populations.

In kidney transplant recipients (KTRs), maintenance therapy with MPA was very high, despite high COVID-19 rates (around 85% of patients). In published KTR cohorts, no specific role of MPA has been identified in the course of COVID-19.¹³ In a single-centre study, the course of COVID-19 in KTR patients was linked to older age but not to immunosuppression intensity and degree of reduction following COVID-19 diagnosis.¹⁴ In iRMD patients, a large US study showed a higher risk of death with chronic use of immunosuppressants compared with patients treated with MTX.⁴ Within this controversial literature, our study is of great interest since we eliminate most of the confounding factors through a PSOW analysis, and no longer find excess

risk of death or an outcome of more severe COVID-19 associated with MPA. This method was never applied to data concerning the risk for severe COVID-19. Observational studies must attempt to adjust for differences contrary to randomised clinical trials.¹¹ In order to replicate the conditions of a randomised trial as closely as possible, we weighted the propensity score to adjust for comparisons between our iRMD patient groups. In addition, the subanalysis of the patient population eligible for this treatment suggests that MPA treatment is not a risk factor for developing severe COVID-19, although larger studies are needed to confirm these findings.

Our results have several limitations, and thus, our results should be considered in the context of overall medical benefit for iRMD patients under consideration for MPA treatment. In our study, the most vulnerable iRMD patients are those with lupus, especially those patients with lupus nephritis,¹⁵ and next, are patients with Systemic sclerosis (SSc), particularly those with ILD.¹⁶ In cases such as these, efficacy of MPA has been demonstrated, and there are limited treatment options available in these disease states.¹⁷ Moreover, RTX is often considered the gold standard for alternative treatment, but RTX has been associated with poor outcomes with COVID-19 in this patient population.⁷ It should be emphasised that our analysis was focused on the risk of excess mortality and/or severe COVID-19 outcome in patients treated with MPA. The safety of MPA treatment and the efficacy of the COVID-19 vaccine with concurrent treatment is also a factor that must be considered but is beyond the scope of the current study. Finally, we cannot exclude that differences in outcomes between the study groups are due to lack of adequate statistical power of MPA patients (n=49). Thus, the present results should be interpreted with caution, and future larger studies should be conducted.

In conclusion, MPA use should be continued in patients requiring the treatment for autoimmune disease, without fear of an increased risk of severe COVID-19. However, patients receiving MPA are also the most vulnerable to severe COVID-19, and COVID-19 vaccinations should be a priority with a close follow-up monitoring of the vaccine response.

Author affiliations

¹Rheumatology Department, University Hospital Centre Bordeaux Pellegrin Hospital Group, Bordeaux, Aquitaine, France

²Department of Biostatistics, CHU Lille, Lille, Hauts-de-France, France

³Department of Internal Medicine, Centre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, Île-de-France, France

⁴Department of Internal Medicine, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France

⁵Department of Internal Medicine, Saint-Eloi Hospital Department of Internal Medicine, Montpellier, Languedoc-Roussillon, France

⁶Department of Internal Medicine and RECIF, Amiens University Hospital, Amiens, France

⁷Université de Picardie Jules Verne, Amiens, Hauts-de-France, France

⁸Unité de Médecine Interne (UF 04): CRMR MATHEC, Maladies auto-immunes et thérapie cellulaire; Centre de Référence des Maladies auto-immunes systémiques Rares d'Île-de-France MATHEC, AP-HP, Hôpital St-Louis, Paris, France

⁹IRSL, Recherche clinique appliquée à l'hématologie, EA3518 (Equipe 3 MATHEC-EUROCORD), Université de Paris, Paris, Île-de-France, France

¹⁰Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France

¹¹Department of General Paediatrics, Infectious Diseases and Internal Medicine, Hopital Universitaire Robert Debre, Paris, Île-de-France, France

¹²Department of Internal Medicine and Clinical immunology, Referral Centre for Rare Systemic Auto-immune Diseases North and North-West of France, Lille University School of Medicine, Lille, France

Twitter Christophe Richez @crichez33

Acknowledgements JetPub Scientific Communications LLC assisted the authors in the preparation of this manuscript, in accordance with Good Publication Practice (GPP3) guidelines.

Collaborators FAI2R/SFR/SNFM/SOFREMIP/CR/IMIDIATE consortium* and contributors**: Contributors, in alphabetical order: Aeschlimann Florence, Paris; Agard Christian, Nantes; Albert Jean-David, Rennes; Alcais Didier, Le Havre; Allain Jean-Sébastien, Rennes; Allanore Yannick, Paris; Amador-Borreiro, Blanca, Paris; Amouzougan, Adamah, Saint-Priest-En-Jarez; Amoura Zahir, Paris; Andre Emma, Paris; Arbault Anaïs, Dijon; Arlet Jean-Benoît, Paris; Arnaud Laurent, Strasbourg; Arniaud Denis, Marseille; Arty-Hue Herliette, Gap; Atlan Lucie, Amboise; Audemard-Vergier Alexandre, Tours; Aubin, François, Besancon; Audoin-Pajot Christine, Toulouse; Audren Victor, Paris; Avenal, Gilles, Rouen; Avouac, Jérôme, Paris; Bach-Bunier Maxime, Colmar; Bacquet-Deschryver Hélène, Dieppe; Bader-Meunier Brigitte, Paris; Balandraud Nathalie, Marseille; Ballot-Schmit, Claire, Besancon; Balblanc Jean-Charles, Trevenans; Bally Stéphane, Chambéry; Banal Frédéric, Saint-Mande; Banneville Béatrice, Paris; Barbery, Pierre, Lisieux; Barrelet Audre, Jossigny; Bart, Géraldine, Rennes; Basch André, Caluire-Et-Cuire; Baumier Vincent, Clermont-Ferrand; Bayer Guillaume, Quincy-Sous-Senart; Bayle Sophie, Avignon; Beauvais Catherine, Paris; Beinat Rudie, Bordeaux; Belin Véronique, Thonon-Les-Bains; Belkhir Rakiba, Kremlin-Bicetre; Benainous Ruben, Bobigny; Belot Alexandre, Bron; Beltai, Aurélie, Narbonne; Benammar Mohammed, Saint-Quentin; Benhamou Mathilde, Versailles; Benhamou Ygal, Rouen; Benmansour Ahmed, Chateauroux; Bennet Pascal, Bois-Guillaume; Bernoux-Manat Brigitte, Rennes; Berthel Elise, Clermont-Ferrand; Berthier, Sabine, Dijon; Berthoud, Olivia, Rennes; Berthoux, Emilie, Lyon; Bertolini Ewa, Annecy; Bigot Adrien, Tours; Bisson-Vaivre Aurélie, Castres; Blaison Gilles, Colmar; Bolla Gilles, Cannes; Bonidan Olivier, Agen; Bonnet Christine, Limoges; Borie, Raphaël, Paris; Bossert Marie, Trevenans; Boudou Laurence, Saint-Chamond; Bouillet, Laurence, Grenoble; Bouhour Françoise, Bron; Bouiller Kévin, Besancon; Borocco, Charlotte, Kremlin-Bicetre; Bouldoires Bastien, Colmar; Bourree, Thomas, Cholet; Boussem, Ines, Paris; Boussoualim Karima, Saint-Priest-En-Jarez; Bouvard Eric, Paris; Brondino Regine, Pennes-Mirabeau; Buchlin Pierre, Mulhouse; Cabantous Laurence, Merignac; Cacoub Patrice, Paris; Cadiou Simon, Rennes; Caplanne, Didier, Bayonne; Cantagrel, Alain, Toulouse; Carteni Maurizio, Saint-Pierre-De-Coutances; Carbasse Aurélie, Montpellier; Castel Brice, Tarbes; Cathébras Pascal, Saint-Priest-En-Jarez; Caumont Hervé, Troyes; Cayot-Bouillet, Audrey, Dijon; Celant Annalisa, Metz; Cerf-Payrastra, Isabelle, Pontoise; Chahinez, Bendahmane, Pontoise; Chaigne Benjamin, Paris; Chaillous Benoît,

Herbiers; Chaffin, Aurélie, Avranches; Champy Romuald, Ecuelles; Charcot Agnès, Paris; Charles Pierre, Paris; Charlot-Lambrecht Isabelle, Reims; Charpin Caroline, Marseille; Chatelus Emmanuel, Strasbourg; Chaudier Bernard, Marseille; Chazerain Pascal, Paris; Chertok Pascale, Argenteuil; Chevalier Xavier, Creteil; Chevreau Maxime, Aix-Les-Bains; Chotard Emilie, Paris; Chu Miow Lin Delphine, Tours; Claudepierre Pascal, Creteil; Clay, Marine, Grenoble; Clavel Gaëlle, Paris; Clavel-Osorio Cyril, Saint-Martin; Clet, Johanna, Bordeaux; Coassy, Astrid, Saint-Priest-En-Jarez; Cohen Fleur, Paris; Cohen Gregory, Avignon; Colette-Cedoz Marie-Eve, Bourgoin-Jallieu; Collecandy Nived, Tours; Constantin, Arnaud, Toulouse; Colombey Antoine, Saint-Nazaire; Comarmond Chloé, Paris; Combe Bernard, Montpellier; Comparon Céline, Bobigny; Constant Elodie, Valence; Coquerelle Pascal, Beuvry; Corli Justine, Douai; Corre Clémence, Vannes; Costedoat-Chalumeau Nathalie, Paris; Couderc, Marion, Clermont-Ferrand; Couret Marie, Bourg-En-Bresse; Courvoisier Natacha, Nogent-Sur-Marne; Coury-Lucas Fabienne, Pierre-Benite; Coutarel Cécile, Clermont-Ferrand; Coutier Fabrice, Vesoul; Damade Richard, Chartres; Daver-Malaterre Laurence, Marseille; Decrock, Marijke, Perpignan; Dehimat Sarahe, Lille; Delahousse Michel, Suresnes; Delattre Barrois Emilie, Quingey; Deligny, Christophe, Fort-De-France; De Moreuil, Claire, Brest; Denarie Delphine, Roanne; Denis, Amélie, Le Mans; Deproux Jeanne, Courbevoie; Derris Emanuelle, Le Mans; Deroux Alban, Grenoble; Desbarbieux Renaud, Boulogne-Sur-Mer; Desdoits, Alexandra, Caen; Descamps Elise, Paris; Deslandre Chantal, Paris; Desmurs Marie, Mulhouse; Despau Jacques, Montelmar; Desplats Marie, Lambersart; Detree Frédéric, Reims; Devauchelle-Pensec Valérie, Brest; Devaux Mathilde, Poissy; Dhote Robin, Bobigny; Diaz, Harmonie, Narbonne; Dieude Philippe, Paris; Dieudonne Yannick, Strasbourg; Diot Elisabeth, Tours; Direz Guillaume, Le Mans; Djeddi Djamel-Dine, Amiens; Domont Fanny, Paris; Douvier Sarah, Aix-Les-Bains; Drouet Béatrice, Pau; Dubost, Jean-Jaques, Clermont-Ferrand; Duc Catherine, Romans-Sur-Isere; Ducornet Angélique, Saint-Brieuc; Dufaure-Lombard Carine, Limoges; Duhamel Alain, Lille; Dumaine Cécile, Paris; Dumel Anne-Elisabeth, Cernay; Dumoulin-Richez Chantal, Mégnac; Duquesne Agnès, Bron; Durand Géraldine, Poitiers; Durandin-Truffinet Mariane, Paris; Duret Pierre-Marie, Colmar; Durieux-Mehlman, Stéphanie, Saint-Cloud; Dusser-Benesty, Perrine, Kremlin-Bicetre; Duval Maïka, Antibes; Ebbo Mikael, Marseille; Ebstein Esther, Paris; Economu-Dubosc Andra, Sucy-En-Brie; El Mahou Soumaya, Tourcoing; Emilie Stéphanie, Villeneuve-Saint-Georges; Euvrand Romain, Bourg-En-Bresse; Evon Philippe, Bar-Le-Duc; Eymard-Gibert, Claire, Lyon; Fabre Sylvie, Montpellier; Fagedet Dorothee, Gap; Farge-Bancel, Dominique, Paris; Farhat Meryem, Lille; Fauconier Marion, Reims; Fautrel Bruno, Paris; Fechtenbaum Jacques, Pantin; Felten Renaud, Strasbourg; Fernandes Fanny, Paris; Ferreira-Maldent Nicole, Tours; Feuer Elodie, Lyon; Fichet Amandine, Trevenans; Flaisler Françoise, Nîmes; Flipo René-Marc, Lille; Florens Nans, Lyon; Foltz, Violaine, Paris; Fontanges Elisabeth, Lyon; Foret Jennifer, Dax; Fougousse Anne-Clare, Saint-Mande; Fouque-Aubert Anne, Lyon; Foutrier-Morello Catherine, Plan-De-Cuques; Francois-Pradier Hélène, Paris; Frantzen Léa, Mulhouse; Fremont, Marie-Luise, Paris; Fritz Pierre, Paris; Froissart Antoine, Creteil; Fulpin Jean, Toulon; Fuzibet Piera, Orleans; Gaches Francis, Toulouse; Gagneux-Lemoussu Laurence, Reims; Gahier Penhoat Mélanie, Saint-Nazaire; Galland Joris, Paris; Gandjbakhch Frédérique, Paris; Gardette, Anaïs, Vichy; Garnier Nicole, Plaisance-Du-Touch; Garraud Thomas, Nantes; Garrot Jean-François, Semur-En-Auxois; Gastaldi Romain, Grenoble; Gaud-Listrat Véronique, Saint-Michel-Sur-Orge; Gaudin, Philippe, Grenoble; Gauthier-Prieur Maud, Louviers; Gauzeur, Loraine, Saint-Denis; Geoffroy, Marion, Reims; Georgescu Dana, Vienne; Georgin-Lavialle Sophie, Paris; Gerard Nathalie, Dijon; Gerber, Anne, Sain-Denis; Gervais Elisabeth, Poitiers; Gibert Eric, Paris; Gill Ghislaine, Paris; Gillard Jérôme, Lons-Le-Saunier; Gilson Mélanie, Grenoble; Gimmonet Pauline, Epernay; Guiraudet-Le Quintrec Jeanine-Sophie, Paris; Giraud-Morelet Aude, Ecully; Glace Baptiste, Vichy; Glanowski Camille, Saint-Mande; Godeau Bertrand, Creteil; Gombert Bruno, La Rochelle; Gonnet-Gracia Camille, La Rochelle; Goupille Philippe, Tours; Gourmelin Olivier, Aix_Les_Bains; Govindaraju-Audouard Sophie, Vesoul; Grados Franck, Amiens; Grall-Lerosey Martine, Rouen; Grardel Bruno, Arras; Grasland Anne, Colombes; Grateau Gilles, Paris; Groza Monica, Colmar; Guggenbuhl, Pascal, Rennes; Guichard, Isabelle, Saint-Priest-En-Jarez; Guillaud Constance, Creteil; Guillaume-Czitrom, Séverine, Kremlin-Bicetre; Guillaume Séverine, Kremlin-Bicetre; Guillibert Caroline, Marseille; Guillot Xavier, Saint-Denis; Guilpain Philippe, Montpellier; Gury Aline, Angers; Guyader, Pauline, Ploemeur; Guyot Marie-Hélène, Roubaix; Hacquard-Bouder Cécile, Yvetot; Havard Marie-Noelle, Argenteuil; Hellier Jean-Pierre, Arles; Hennequin Pascal, Epinal; Henriot Basile, Dinan; Henry Julien, Kremlin-Bicetre; Hentgen Véronique, Le Chesnay; Hermet Marion, Vichy; Herasse Muriel, Lyon; Hernandez Julie, Montauban; Hie Miguel, Paris; Hilliquin Pascal, Corbeil-Essonnes; Hirschberger Olivier, Mulhouse; Hittinger-Roux Ambre, Reims; Holubar Jan, How Shing Koy, Elsa, Saint-Priest-En-Jarez; Montpellier; Hua, Charlotte, Nîmes; Hudry Christophe, Paris; Huguenel Serge, Sarrebourg; Jaccard Clara, Clermont-Ferrand; Jacquemier Jean-Michel, Cornebarrieu; Jamarid Bénédicte, Toulouse; Jan Catherine, Bar-Le-Duc; Jean Sylvie, Rennes; Jousse-Joulin, Sandrine, Brest; Jourvay Mathieu, Arras; Juge Pierre-Antoine, Paris; Juillard Laurent, Lyon; Jullien Denis, Lyon; Joffres, Laurie, Saint-Benoit; Kabala Anna, Bordeaux; Kabchou Abdelkrim, Vichy; Karkowski Ludovic, Lyon; Karman Françoise, Pontault-Combault;

Kemiche Farid, Pontoise; Keraen Jérémy, Quimper; Kieffer Pierre, Mulhouse; Kone-Paut Isabelle, Krebs, Stéphanie, Ploemeur; Kremlin-Bicetre; Koreichi Abdeldajjalil, Lorient; Kostine Marie, Bordeaux; La Batide Alanore Sylvain, Paris; Lafforgue Pierre, Marseille; Lahalle Sophie, Paris; Lambert Marc, Lille; Lambrecht Isabelle, Reims; Lamer, François, Rennes; Langlois Vincent, Le Havre; Lanot Sylvain, Alençon; Lanteri Aurélie, Antibes; Larbre Jean-Paul, Pierre-Benite; Latourte Augustin, Paris; Lavigne Christian, Angers; Le Guen Guegan Sophie, Contamine-Sur-Arve; Le Guenno Guillaume, Clermont-Ferrand; Leguy Diane, Roubaix; Leguy-Sueguin, Vanessa, Dijon; Lebrun Agnès, Paris; Ledout Emmanuel, Tourcoing; Le Gouellec, Noémie, Valenciennes; Legoupil Nathalie, Paris; Legrand Erick, Angers; Lejeune Charlotte, Lille; Leloire Olivier, Ronchin; Leroux Christophe, Dreux; Leroy Rémi, Dunkerque; Leroy-Gouix Marie, Vannes; Leske, Charles, Cholet; Leturcq Tifenn, Paris; Leurs Amélie, Dunkerque; Leveque-Michaud Céline, Valence; Limbach François-Xavier, Saverne; Liote Frédéric, Paris; Lohse Anne, Trevenans; Lozac'h Pierre, Le Mans; Lucas, Charles, Rennes; Mabrut, Etienne, Pierre-Benite; Madelon Aurélie, Grenoble; Maillot, François, Tours; Magnol, Marion, Toulouse; Magy-Bertrand Nadine, Besançon; Mahevas Matthieu, Creteil; Maillard Hélène, Lille; Maillot Thibault, Macon; Malochet-Guinamand Sandrine, Clermont-Ferrand; Mankikian, Julie, Tours; Mangon Quentin, Angers; Marchou-Lopez Sylvie, Crolles; Margarit Nathalie, Portet-Sur-Garonne; Marhadour Thierry, Brest; Maria Alexandre, Montpellier; Mariette Xavier, Kremlin-Bicetre; Marotte Hubert, Saint-Priest-En-Jarez; Martin, Thierry, Strasbourg; Mathian Alexis, Paris; Mathieu, Sylvain, Clermont-Ferrand; Maurier François, Metz; Maury Frédéric, Beuvry; Mazed-Guillaume Betty, Angers; Mazouyez Arnaud, Contamine-Sur-Arve; Mazyad Hassan, Poissy; Mehseu-Cetre Nadia, Bordeaux; Meinerz Ulrich, Paris; Mekinian Arsène, Paris; Merci, Jean-Camille, Ales; Messer Laurent, Colmar; Miceli Corinne, Paris; Michaud Martin, Toulouse; Michel Catherine, Mulhouse; Michel Matthias, Sangatte; Michon Mathilde, Courbevoie; Milesi-Lecat Anne-Marie, Vichy; Molto Anna, Paris; Moly Marie, Montpellier; Moranne Olivier, Nîmes; Morel Gautier, Valenciennes; Morel Hugo, Dijon; Morel Jacques, Montpellier; Morin Franck, Saint-Pierre-De-Coutances; Moulinier Laurence, Paris; Moulis Guillaume, Toulouse; Moura Bertrand, Paris; Naude, Claudine, Saint-Jean-De-Maurienne; Nguyen Minh, Paris; Nicolas-Vullierme Sabine, Chatillon; Nielly Hubert, Saint-Mande; Nocturne Gaétane, Kremlin-Bicetre; Nottez Aurore, Dunkerque; Olivier, Anne, Angers; Ollagnon Henri-Olivier, Villeurbanne; Ozol, Eric, Beziers; Pacaud-Vitoux Isabelle, Guilherand-Granges; Padern, Guillaume, Montpellier; Pagnier Anne, Grenoble; Paris Caroline, Marseille; Parrot Antoine, Paris; Pascart Tristan, Lille; Pascaud-Mansour Yasmina, Angers; Paulin Lætitia, Bourgoin-Jallieu; Pavy Stephan, Kremlin-Bicetre; Payet, Judith, Saint-Denis; Perard Laurent, Lyon; Pers Yves-Marie, Montpellier; Pereira-Gillion, Céline, Tours; Pertuiset Edouard, Petit, Juliette-Louise, Paris; Pontoise; Pha Micheline, Paris; Pham Thao, Marseille; Pichon Maud, Argenteuil; Pierreisnard Audrey, Merignac; Pizana Gabrielle, Fougères; Poignant Sylvaine, Nantes; Poix Elsa, Quint-Fonsegrives; Portier Agnès, Paris; Pouchot, Jacques, Paris; Poulet Antoine, Marseille; Poursac, Nicolas, Bourdeaux; Pugnet Grégory, Toulouse; Puyraimond-Zemmour Deborah, Paris; Quartier-Dit-Maire Pierre, Paris; Quenet Marion, Saint-Brieuc; Queyrel Viviane, Nice; Raffray Loïc, Saint-Denis; Razanamahery, Jérôme, Dijon; Remy Philippe, Creteil; Remy, Piera, Creteil; Renard Myriam, Aix-Les-Bains; Rene Jessica, Tours; Revuz Sabine, Metz; Rey Bénédicte, Lyon; Richard-Colmant Gaëlle, Lyon; Richer, Olivier, Bourdeaux; Lyon; Riviere Etienne, Bourdeaux; Riviere Sébastien, Paris; Robin Sophie, Elbeuf; Rohmer Julien, Suresnes; Roitg Isabelle, Perpignan; Romier Mélanie, Lyon; Rolland Michel, Saint-Etienne; Roriz Mélanie, Agen; Rosenberg Carole, Argenteuil; Rossi Linda, Kremlin-Bicetre; Roth Olivier, Marseille; Rouidi Sid-Ahmed, Dreux; Roumier Mathilde, Suresnes; Rousiere Mickaël, Paris; Rousselin Clémentine, Valenciennes; Rouviere Bénédicte, Brest; Roux Christian, Nice; Roux Fabienne, Paris; Roux Marielle, Bourgoin-Jallieu; Roux Nicolas, Metz; Rouzaud Diane, Paris; Rozenberg Sylvie, Paris; Ruysen-Witrand, Adeline, Toulouse; Sacco Isabelle, Paris; Sadjji Fatima, Poissy; Sailer Laurent, Toulouse; Salliot Carine, Orleans; Samjee, Isabelle, Rennes; Salmon Jean-Hugues, Reims; Samaille, Charlotte, Lille; Samson, Maxime, Dijon; Saraux Alain, Saunier, Jordane, Lyon; Savey, Léa, Paris; Brest; Seguiet Julie, Marseille; Sellam Jérémie, Paris; Senbel Eric, Marseille; Sene Thomas, Paris; Senet Patricia, Paris; Seror, Raphaële, Kremlin-Bicetre; Servettaz Amélie, Reims; Seve, Pascal, Lyon; Sicaud Aurélie, Le Pont-De-Beauvoisin; Sivova, Nadia, Tourcoing; Smets Perrine, Clermont-Ferrand; Sobanski Vincent, Lille; Sordet Christelle, Strasbourg; Sornay-Rendu Elisabeth, La Tour-Du-Pin; Soubrier, Martin, Clermont-Ferrand; Souchaud-Debouvier Odile, Poitiers; Sourisseau-Diverres, Gaëlle, Gujan-Mestras; Sparsa Lætitia, Mulhouse; Spielmann Lionel, Colmar; Steib Sarah, Aubagne; Stavris Chloé, Marseille; Straus Catherine, Elancourt; Strotz Victor, Antony; Szafors Paulina, Montpellier; Taffignon-Clave Séverine, Ecully; Talmud, Deborah, Orleans; Taraud, Chloé, Niort; Simoens Justine, Lille; Theillac Claire, Pierre-Benite; Tenenbaum Nora, Paris; Thomachot Benoît, Gardanne; Thomas Thierry, Saint-Priest-En-Jarez; Tieulle Nathalie, Nice; Tiriou Soizic, Nantes; Tison Alice, Bourdeaux; Tournadre, Anne, Clermont-Ferrand; Toussiroit Eric, Besançon; Trefond Ludovic, Clermont-Ferrand; Trijau Sophie, Marseille; Trouillier Sébastien, Aurillac; Trouvin Anne-Priscille, Paris; Uettwiller, Florence, Tours; Ulrich Marc, Valenciennes; Uzunhan, Yurdagul, Bobigny; Vaquier Jacques, Limoges; Valls-Bellec, Isabelle, Brest; Veillard Eric, Saint-Malo; Veillon Laurent, Orleans; Vial Guillaume, Bourdeaux; Viillard Jean-François,

Bordeaux; Victor Judith, Bourdeaux; Vidon Claire, Aix_Les_Bains; Vidon Mathias, Creteil; Vigne Camille, Pierre-Benite; Virone Alexandre, Kremlin-Bicetre; Warzocha Ursula, Bobigny; Wendling Daniel, Besançon; Werle Claude, Haguenau; Wibaux Cécile, Seclin; Wisniewski Michel, Saint-Amand-Les-Eaux; Woessner Juliette, Avignon; Xerri-Campano Bernadette, Saint-Maur-Des-Fosses.

Contributors M-ET is the guarantor and brought substantial contributions to the conception and design of the work, the analysis and interpretation of data for the work, and in drafting the work, and in final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. ED, TB and CM brought substantial contributions to the analysis and interpretation of data for the work, in revising the manuscript critically for important intellectual content, final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MD, TG, AM, JS, NAA, IM and EH brought substantial contributions to the acquisition of data for the work; in revising the work critically for important intellectual content; in final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. CR brought substantial contributions to the conception or design of the work; in revising the work critically for important intellectual content; in final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The study was performed in compliance with MR-004, received permission from Lille University Hospital, was declared to the Commission Nationale de l'Informatique et des Libertés (CNIL reference DEC20-107) and was registered on ClinicalTrials.gov.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Marie-Elise Truchetet <http://orcid.org/0000-0001-8045-0180>

Isabelle Melki <http://orcid.org/0000-0002-8057-333X>

Eric Hachulla <http://orcid.org/0000-0001-7432-847X>

Christophe Richez <http://orcid.org/0000-0002-3029-8739>

REFERENCES

- 1 Richez C, Lazaro E, Lemoine M, *et al*. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. *Joint Bone Spine* 2020;87:187–9.
- 2 Monti S, Balduzzi S, Delvino P, *et al*. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis* 2020;79:667–8.
- 3 Kroon FPB, Najm A, Alunno A, *et al*. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. *Ann Rheum Dis* 2022;81:422–32.

- 4 Strangfeld A, Schäfer M, Gianfrancesco MA, *et al.* Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis* 2021;80:930–42.
- 5 Landewe RBM, Kroon FPB, Alunno A. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. *Ann Rheum Dis*;2022.
- 6 FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. *Ann Rheum Dis* 2021;80:527–38.
- 7 Avouac J, Drumez E, Hachulla E, *et al.* COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. *Lancet Rheumatol* 2021;3:e419–26.
- 8 Fanouriakis A, Kostopoulou M, Alunno A, *et al.* 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019;78:736–45.
- 9 Kowal-Bielecka O, Franssen J, Avouac J, *et al.* Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017;76:1327–39.
- 10 CNIL. Recherches n'impliquant pas la personne humaine, études et évaluations dans le domaine de la santé Méthodologie de référence MR-004. Available: <https://www.cnil.fr/fr/declaration/mr-004-recherches-nimpliquant-pas-la-personne-humaine-etudes-et-evaluations-dans-le> [Accessed 10 Jun 2020].
- 11 Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. *JAMA* 2020;323:2417–8.
- 12 Ugarte-Gil MF, Alarcón GS, Izadi Z, *et al.* Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. *Ann Rheum Dis* 2022;81:970–8.
- 13 Lum E, Bunnapradist S, Multani A, *et al.* Spectrum of coronavirus disease 2019 outcomes in kidney transplant recipients: a single-center experience. *Transplant Proc* 2020;52:2654–8.
- 14 Santeusano AD, Menon MC, Liu C, *et al.* Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). *Clin Transplant* 2021;35:e14221.
- 15 Fanouriakis A, Kostopoulou M, Cheema K, *et al.* 2019 update of the joint European League against rheumatism and European renal Association–European dialysis and transplant association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. *Ann Rheum Dis* 2020;79:713–23.
- 16 Volkmann ER, Tashkin DP, Li N, *et al.* Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. *Arthritis Rheumatol* 2017;69:1451–60.
- 17 Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. *Nat Rev Rheumatol* 2020;16:167–78.